Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2022
2022 World Conference on Lung Cancer
As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
-
+
OA03 - Molecular Targeted Treatments
- Type: Oral
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Presentations: 11
- Moderators:Andrew Ciupek
- Coordinates: 8/07/2022, 14:30 - 15:40, Hall C7
-
+
OA03.01 - Session Introduction
14:30 - 14:31 | Author(s): Andrew Ciupek
- Abstract
Loading... -
+
OA03.02 - Session Introduction
14:31 - 14:32 | Author(s): David R. Gandara
- Abstract
Loading... -
+
OA03.03 - Sotorasib in Combination with RMC-4630, a SHP2 Inhibitor, in KRAS p.G12C-Mutated NSCLC and Other Solid Tumors
14:32 - 14:42 | Author(s): Gerald Falchook
- Abstract
Loading... -
+
OA03.04 - Phase I A Study to Evaluate GDC-6036 Monotherapy in Patients with Non-small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation
14:42 - 14:52 | Author(s): Adrian Sacher
- Abstract
Loading... -
+
OA03.05 - Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C
14:52 - 15:02 | Author(s): Michael Thomas
- Abstract
Loading... -
+
OA03.06 - CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC
15:02 - 15:12 | Author(s): Bob T. Li
- Abstract
Loading... -
+
OA03.07 - Safety and Efficacy of D-1553 in Patients with KRAS G12C Mutated Non-Small Cell Lung Cancer: A Phase 1 Trial
15:12 - 15:22 | Author(s): Shun Lu
- Abstract
Loading... -
+
OA03.08 - Discussant
15:22 - 15:32 | Author(s): Helena Linardou
- Abstract
Loading... -
+
OA03.09 - Live Q&A
15:32 - 15:40
- Abstract
Loading... -
+
Session Moderator
15:32 - 15:40 | Author(s): Andrew Ciupek
- Abstract
Loading... -
+
Session Moderator
15:32 - 15:40 | Author(s): David R. Gandara
- Abstract
Loading...
-
+
P2.12 - Tumor Biology and Biomarkers - Immune Biology & Immunotherapy
- Type: Regular Poster
- Track: Tumor Biology and Biomarkers - Immune Biology & Immunotherapy
- Presentations: 5
- Coordinates: 8/08/2022, 17:15 - 19:15, Exhibit Hall - Hall B
-
+
P2.12-03 - External Validation of a Novel CT-Based Prognostic Radiomic Signature in Patients With Metastatic NSCLC in SWOG S0819 Phase III Randomized Trial
Author(s): Laurent Dercle- Abstract
Loading...
-
+
MA13 - Update on ROS1 Inhibitors and New Pathways
- Type: Mini Oral
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Presentations: 13
- Moderators:Lorenza Landi
- Coordinates: 8/09/2022, 12:00 - 13:00, Hall C7
-
+
MA13.08 - A Phase 1 Trial of Sapanisertib and Telaglenastat (CB-839) in Patients With Advanced NSCLC (NCI 10327): Results from Dose Escalation
12:32 - 12:37 | Author(s): Jonathan Riess
- Abstract
Loading...
